Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Teva's Weltruza (olanzapine) wins FDA approval as once-monthly injectable treatment for schizophrenia
Small molecule, neurological, long-acting injectable, schizophrenia, olanzapine, atypical antipsychotic - Read more

FDA approves Roche's Tecentriq (atezolizumab) for Stage III mismatch repair deficient colon cancer based on Ph3 data
Antibody, cancer, monoclonal antibody, colorectal cancer, PD-L1, combination therapy - Read more

GSK joins Chai Discovery's AI drug discovery platform following successful wet-lab validation of protein designs
Licensing deal, AI/ML, drug discovery, antibody, R&D - Read more

Profound Medical, Telix Pharmaceuticals enter co-education agreement advancing PSMA-informed prostate cancer care
Co-education agreement, oncology, diagnostics, AI/ML, commercialization - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

Innovent Biologics' Sycume (teprotumumab N0) meets Ph3 primary endpoint in inactive thyroid eye disease
Antibody, autoimmune, monoclonal antibody, thyroid eye disease, IGF-1R - Read more

Endeavor BioMedicines' taladegib (ENV-101) advances to Ph3 after Ph2b win in idiopathic pulmonary fibrosis
Small molecule, pulmonary fibrosis, Hedgehog pathway inhibitor, idiopathic pulmonary fibrosis, fibrosis - Read more

Alumis' (envudeucitinib) Ph3 data show rapid, durable improvements in moderate-to-severe plaque psoriasis across scalp, itch, and quality of life
Small molecule, autoimmune, TYK2 inhibitor, plaque psoriasis, JAK pathway - Read more

Pharvaris' (deucrictibant) Ph3 results show rapid efficacy in hereditary angioedema attacks
Small molecule, autoimmune/inflammatory, bradykinin B2 receptor antagonist, hereditary angioedema, on-demand treatment - Read more

Johnson & Johnson's ICOTYDE (icotrokinra) Ph3 two-year data show durable skin clearance in moderate-to-severe plaque psoriasis
Protein therapy, autoimmune, oral peptide, plaque psoriasis, IL-23 receptor, long-term efficacy - Read more

TRex Bio prices $117M IPO to advance immune-regulating Treg-targeted drug pipeline
Autoimmune, regulatory T cells, fusion protein, clinical-stage, inflammatory disease - Read more

Retension Pharmaceuticals prices $45M IPO to advance hypertension cardiovascular disease treatments
Cardiovascular, clinical-stage, small molecule, hypertension - Read more

X4 Pharmaceuticals enters up to $150M term loan facility with K2 HealthVentures
Small molecule, rare disease, clinical-stage - Read more

Tang Capital Acquisition files for $75M IPO, targeting development-stage biopharma companies
SPAC, biopharma, development-stage - Read more

Vinci Pharmaceuticals raises over $8M Series A, advancing sustained drug delivery platform for retinal diseases
Ophthalmology, retinal disease, drug delivery, implant technology, clinical-stage - Read more

Sunshine Biopharma closes $6M public offering, oncology and antiviral prescription medications company
Oncology, antiviral, small molecule, specialty pharmaceuticals - Read more

Quince Therapeutics relaunches as IRulya Therapeutics, refocusing on lung disease after merger with Orphai Therapeutics
Small molecule, pulmonary disease, strategic, major transaction, financial - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Revolution Medicines stock drops 6.3% as FDA review documents reveal Rasonque's weaker KRAS G12D subgroup performance
Small molecule, oncology, competitive, financial - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here